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Snakebite envenoming is a major public health problem among rural communities of the Nigerian savanna. The
saw-scaled or carpet viper (Echis ocellatus) and, to a lesser extent, the African cobras (Naja spp.) and puff adders
(Bitis arietans) have proved to be the most important cause of mortality and morbidity. The main clinical features of
E. ocellatus envenoming are systemic hemorrhage, incoagulable blood, shock, local swelling, bleeding and,
occasionally, necrosis. Bites may be complicated by amputation, blindness, disability, disfigurement, mutilation,
tissue destruction and psychological consequences. Antivenom remains the hallmark and mainstay of envenoming
management while studies in Nigeria confirm its protection of over 80% against mortality from carpet-viper bites.
However, the availability, distribution and utilization of antivenom remain challenging although two new
antivenoms (monospecific EchiTab G and trispecific EchiTab ICP-Plus) derived from Nigerian snake venoms have
proven very effective and safe in clinical trials. A hub-and-spoke strategy is suggested for broadening antivenom
access to endemic rural areas together with instituting quality assurance, standardization and manpower training.
With the advent of antivenomics, national health authorities must be aided in selecting and purchasing antivenoms
appropriate to their national needs while manufacturers should be helped in practical ways to improve the safety,
efficacy and potential coverage against snake venoms and pricing of their products.
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Snakebite envenoming comprises a major public health
problem among communities of the savanna region of
West Africa, notably in Benin, Burkina-Faso, Cameroon,
Ghana, Nigeria and Togo [1-4]. The precise incidence of
snakebite is difficult to determine and is often grossly
underestimated but a global reappraisal estimated the
occurrence in the West African region of 10,001 to
100,000 snakebite envenomings with an incidence of
8.9-93.3/100,000 persons per year with an estimated
1001 to 10,000 deaths and a mortality rate of 0.5-5.9/
100,000 persons per year [5]. A more recent study using
a meta-analytic approach estimated that over 314,000
bites, 7,300 deaths and nearly 6,000 amputations occur
from snakebites annually in Sub-Saharan Africa [6].Correspondence: abdulrazaq_habib@yahoo.co.uk
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Overview of snakebites in Nigeria
In parts of the Nigerian savanna snakebite victims may
occupy over 10% of hospital beds. In the Benue valley of
Nigeria, the estimated incidence is as high as 497 per
100,000 population per year with 10 to 20% comprising
untreated fatalities [1,7]. The saw-scaled or carpet viper
(Echis ocellatus) has proved to be the most important
cause of snakebite mortality and morbidity in the region
(Figure 1).
The African cobras (Naja spp.), puff adders (Bitis
arietans) (Figure 1) and mambas (Dendroaspis spp.) are fre-
quently involved in attacks on humans while Atractaspis
spp. and small vipers are only occasionally involved [1,8-11].
Snakebite affects farmers, nomads and rural dwellers of all
ages. The main clinical features of E. ocellatus envenoming
are systemic hemorrhage, incoagulable blood, shock, local
swelling, bleeding and occasionally necrosis [1,8,12]. All
body systems may be affected; cardiac and hemodynamic
abnormalities may result while the strongest predictor ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Carpet viper, African spitting cobra and puff adder.
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intracranial hemorrhage [13-15]. Neurotoxicity has been
reported following Egyptian cobra (Naja haje) bites in cer-
tain parts of the country. Occasionally, snakebite may lead
to important complications such as amputation, blindness
resulting from spitting cobra (Naja nigricollis) venom,
opthalmia, fetal loss, and wound infection, tetanus and
scarring with potential for malignant transformation, and
psychological consequences e.g., excessive anxiety, stress,
hysteria and worry [16-19].
Economic impact of snakebite
The burden of human suffering caused by snakebites has
been greatly underestimated, ignored and neglected for
far too long. Snakebites, common in rural areas of many
tropical developing countries including Nigeria, mainly
affect the youth or agricultural workers who lack a polit-
ical voice that effectively represent their needs. From the
foregoing, it is evident that several thousand Nigerians
fall victims of snakebites annually. These are mostly
farmers, herdsmen and their rural-dwelling families.
Each bite, whether or not accompanied by envenoming,
leads to loss of work days. The high-risk groups are also
the economically active population, so that their
prolonged or short-term incapacitation at periods which
coincide with the most intense farming activities can
only lead to reduced agricultural production and low
economic performance [20].
Furthermore, a recent study of 109 snakebite victims
showed through multivariate analysis that delayed pres-
entation beyond 24 hours after the bite (adjusted OR:
5.8; 95% CI: 2.0-17.0) and hospital stay over two days
(adjusted OR: 19.5; 95% CI: 2.0-192.3) constitute inde-
pendent risk factors for high-cost care [21]. Apart from
loss of work days, the victims and their families have to
bear the cost of treatment which can be quite high. It is
not unusual for families to sell one or more cattle or a
substantial portion of their harvest to pay for such treat-
ment. In addition, a variable but unacceptably high per-
centage of victims die or are left with permanent
mutilation each year. This constitutes a major liability to
the families, since the victims are usually the breadwinnerswhose absence constitutes a permanent loss to the man-
power resources available for the agricultural sector [20].
Even the fear of snakebite keeps many people away from
such economic activities as peri-domestic poultry farming,
a favorite haunt of Naja nigricollis or from working late
on the farm for fear of being bitten on the way home in
the darkening hours of the evening.
Recently, snakebite-induced mortality was shown to
be inversely correlated with the Human Development
Index, the per capita government expenditure on
health and gross domestic product per capita, and
directly associated with the percentage of the labor
force in agriculture. It was further shown that snake
envenoming is negatively associated with governmen-
tal expenditure on health, thus reaffirming its status as a
disease of the poor [22]. Clearly therefore, poverty predis-
poses to snakebite and it is not only a major health prob-
lem but it is also a major impediment to economic
prosperity.
Future health economic studies should factor in not
only the burden of mortality but also the consequences
resulting from amputation, blindness, disability, disfigure-
ment, mutilation and tissue destruction [16-19]. In par-
ticular studies should derive quantitative estimates of
economic and productivity losses by computing disability-
adjusted life years (DALYs) and quality-adjusted life years
(QALYs).
First-aid and pre-hospital care
First aid measures include reassurance of patients and
immobilization of the bitten limb with a splint or sling.
First aid administrators should hasten the transfer of pa-
tients to a hospital along with the dead snake if found.
Avoid harmful and time-wasting procedures such as in-
cisions for application of native herbs, ice packs or elec-
tric shock, which have not yet been confirmed to be
effective in controlled studies [23]. Avoid the use of
tourniquets, constricting bands etc., as they have been
shown to have minimal or no beneficial effect unless the
snake was identified as dangerously neurotoxic, such as
N. haje and Dendroaspis spp., since it may worsen ische-
mia and necrosis [24].
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snakebite victims at a hospital in north central Nigeria
were reported. The primary outcome assessed was death
or disability at hospital discharge. Victims were predom-
inantly male farmers, and in 54 cases (75%) the snake
was identified as a carpet viper (Echis ocellatus), with
the remainder unidentified. Most subjects (n = 58, 81%)
attempted at least one first aid measure after the bite, in-
cluding tourniquet application (n = 53, 74%), application
(n = 15, 21%) or ingestion (n = 10, 14%) of traditional
concoctions, bite site incision (n = 8, 11%), black stone
application (n = 4, 5.6%), or suction (n = 3, 4.2%). The
majority (n = 44, 61%) presented late (after four hours).
Most (n = 53, 74%) were fully recovered at hospital dis-
charge. Three deaths (4.2%) and thirteen (18%) disabil-
ities (mainly tissue necrosis) occurred. The use of any
first aid was associated with a longer hospital stay than
no use (4.6 ± 2.0 days versus 3.6 ± 2.7 days, respectively,
p = 0.02). The antivenom requirement was greater in sub-
jects who had used a tourniquet (p = 0.03) and in those
who presented late (p = 0.02). Topical application (OR: 15,
95% CI: 1.4-708) or ingestion of traditional concoctions
(OR: 20, 95% CI: 1.4-963) was associated with increased
risk of death or disability. Ingestion or application of con-
coctions was associated with a longer time interval before
presentation, a higher cost of hospitalization, and an in-
creased risk of wound infection [25].
All victims should be admitted to hospitals for at least
24 hours except in the case of a clearly non-venomous
bite where the snake has been reliably identified. Pain
may be managed with either oral paracetamol or nar-
cotics. Persistent vomiting may be treated with intraven-
ous chlorpromazine or other antiemetics. Intramuscular
injections should be avoided because of susceptibility to
hematoma formation in carpet viper bites.
Antivenoms in Nigeria
Studies in Nigeria confirm that antivenom, which remains
the mainstay in the management of envenomings, confers
protection of over 80% against mortality from carpet viper
bites [26]. However, in the last twenty years, a crisis in
antivenom supply to sub-Saharan Africa has become evi-
dent [27,28]. The causes are complex but involve: a lack of
commercial incentives for the companies that used to pro-
duce anti-venoms for Africa and inefficient distribution
channels within the national health systems; ignorance of
true antivenom requirements due to poor epidemiological
information; the high cost of some products which make
them unaffordable to local health systems; and loss of con-
fidence in antivenoms, due partly to the marketing of inef-
fective and inappropriate products imported from
overseas [27,29-31]. All these elements have contributed
to a descending spiral of antivenom supply in sub-Saharan
Africa and rising snakebite mortality and morbidity.The gravity of this situation has prompted a growing
concern. Since the 1990s, the Nigerian Ministry of Health
has become increasingly aware of the medical importance
of snakebite and the crisis in antivenom supply. Nigeria-
UK collaborations were initiated to provide effective
antivenoms. This resulted in the formation of the EchiTAb
Study Group (Nigeria-UK) which, in 1995, developed the
original EchiTAb (MicroPharm), an ovine Fab monospe-
cific antivenom against Nigerian E. ocellatus venom. This
antivenom was clinically tested and found to be effective,
but because of its association with the problem of recur-
rent symptoms of envenoming, work continued to develop
an antivenom with a more durable effect [12]. Currently,
EchiTAb-G (a monospecific antivenom manufactured
by Micropharm) and EchiTAb-Plus-ICP (a trispecific
antivenom manufactured by Instituto Clodomiro Picado,
University of Costa Rica) have been developed against
venoms of Nigerian snakes [32].
In recently conducted clinical trials in Kaltungo hos-
pital, Nigeria, comparing the two antivenoms in 400 E.
ocellatus-envenomed patients with incoagulable blood,
the antivenoms were found to be acceptably safe and
durably effective [33]. At six hours, none of the partici-
pants had died and clotting had been permanently re-
stored in 76% and 83% of patients on EchiTAb-G and
EchiTAb-Plus-ICP, respectively. Further developments
in response to the crisis include the commitment of
several manufacturers to produce antivenoms for the
region. Thus, in addition to laboratories that have
previously manufactured antivenoms for Africa, such
as EgyVac (Egypt), Sanofi-Pasteur (France) and South
African Vaccine Producers, new manufacturers have
entered the market including MicroPharm (UK) and
Instituto Clodomiro Picado (Costa Rica), and the Instituto
Bioclon (Mexico) [32,34]. This expansion greatly im-
proves the prospects for better treatment of snakebite
envenoming.
Access to effective antivenom
Use of inappropriate or ineffective antivenoms following
envenoming independently predicts mortality [15,30,31].
It is necessary that the regulatory authorities in the
countries of the region ensure the procurement and dis-
tribution of appropriate antivenoms raised against locally
prevalent snakes. Unscrupulous marketing of inappro-
priate products has had disastrous consequences. The
use of such antivenoms has increased mortality and con-
versely, regionally appropriate antivenoms has reduced
mortality by 70 to 90% [15,30].
Indeed, a delay in administering effective anivenom
predicts the likelihood of dying; an hour’s delay before
antivenom administration is associated with a 1% in-
creased risk of dying [15]. The following three models of
delay in maternal mortality may indeed be similar and
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medical help for snakebite emergency for reasons of
cost, lack of recognition of an emergency, poor educa-
tion, lack of access to information and gender inequality;
(2) delay in reaching an appropriate facility for reasons
of distance, infrastructure and transport; (3) and delay in
receiving adequate care when a facility has been reached
due to shortages in qualified staff or unavailability of
medical supplies (e.g., reliable antivenoms).
While distance from bite location to facilities with
available stock of effective antivenom is not the sole de-
terminant of delay, it is probable that distributing and
providing antivenoms in relatively inaccessible rural en-
demic areas might reduce the distance travelled by vic-
tims and improve access to care [15].
A possible strategy for improving access would be to
consider a hub-and-spoke model (also referred to as
cluster model) for snakebite care and treatment. In this
model, a secondary or higher-level hospital would be
the hub while pairs of health facilities 20 to 30 km
away (a district hospital and nearby village comprehensive
health center) would constitute the spokes [Figure 2].
Attempts should be made to identify all patients that
only seek traditional medicine practitioners and those
that die in the community and link them with periph-
eral facilities. These lower level facilities (which nor-
mally do not stock antivenom) would thence provide
and administer antivenoms based on case manage-
ment protocol (CMP). This proposal includes tech-
nical oversight from the higher facility at the hubFigure 2 Hub-and-spoke model for snakebite care. Full meaning of acr
AntiVenom; CHC: Comprehensive Health Centre; CHEW: Community Health
QA-QC: Quality Assurance Quality Control; TOT: Training of Trainers; 20WBCwhich would include step-down trainings, standardiza-
tions and the use of CMP by a lower cadre of staff
often with no medical doctor in such rural facilities.
Given that antivenoms also have the potential to pro-
voke anaphylactic reactions and serum sickness, it is im-
portant that CMP balances treatment information on
use of antivenom, its benefit, and the detection and
management of adverse reactions. Antivenoms and com-
plementary items (analgesics, tetanus toxoid and anti-
sera, parenteral fluid, wound care consumables etc.)
should be made available regularly in health care centers
rather than by demand. All envenomed patients present-
ing at these facilities, together with their clinical features,
management and outcome should be recorded prospect-
ively over time, thereby improving the epidemiological
data gathered on the rural snakebite burden (Figure 2).
Subsequently, the hub-and-spoke strategy should be
evaluated in a community cluster randomized controlled
trial in which some pairs are randomly selected to re-
ceive a training program to manage uncomplicated
snakebite, administer antivenom, as well as detect and
manage adverse reactions. This will serve as the inter-
vention arm while other pairs will serve as a comparator
and offer the current standard of care, i.e. refer snake-
bitten patients to secondary or higher-level facilities for
care. Ultimately, such a study will allow determination
of the effectiveness of antivenoms in routine practice in
villages (as against efficacy estimated from clinical trials);
the effect of reducing delay on outcome; adverse drug
reactions detection in villages by lower-level health careonyms: ADR: Adverse Drug Reactions; ASV: Anti-Snake Serum
Extension Worker; MD: Medical Doctors; PCV: Packed Cell Volume;
T: 20 minute Whole Blood Clotting Test.
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in antivenom distribution/replenishment at lower levels
of the health system as a prelude to adoption of the
strategy for maintaining a nationwide supply of anti-
venom (Figure 2).
Quality assurance, standardization and training
Even in the presence of appropriate and effective anti-
venom, the importance of education, standardization,
training and overall quality assurance should not be
underestimated. In a study conducted in Mathias Hospital,
Yeji, northern Ghana, snakebite cases were an important
cause of morbidity and mortality with a case fatality rate
of 11% (8/72). But prior to instituting intervention mea-
sures, case management difficulties included uncertainty
about the assessment of the envenoming severity, the anti-
venom dosage and the response to treatment. Subse-
quently, an intervention package comprised of several
components including development of a treatment proto-
col, staff training, monitoring of compliance and patient
education was introduced.
During a 33-month post-intervention period there was
excellent protocol compliance, fewer snakebite compli-
cations, and a fall in the mortality rate to 1.3% (3/238),
that is, a 90% reduction compared with a 15-month
baseline review. There was a 50% increase in snakebite
admissions and fewer delays. The authors concluded by
recommending a similar quality assurance strategy, in-
volving case review and the use of a treatment protocol with
monitoring of compliance to sustain improved snakebite
outcomes in comparable settings, particularly if inexperi-
enced staff are involved in care [4]. Such standardization
approaches should be widely introduced in areas endemic
for bites.
Conclusions
Prevention and future perspectives
As a preventive measure, protective clothing, including
boots and long trousers, should be worn whilst working
in snake-infested areas. Improved techniques of effective
and safer antivenom production (e.g., whole immuno-
globulin versus digested fragments) and best formula-
tion with extended shelf life (freeze-dried versus liquid
formulation) in an African setting should be critically
explored.
The field of proteomics (venomics, antivenomics) will
continue to complement preclinical studies and clinical
trials in evaluating antivenoms for use in the region. The
proteomics approach brings with it the potential to de-
sign new immunizing mixtures from which to raise po-
tent antivenoms with wider therapeutic coverage/ranges
[35]. Already, activity spectra of coverage of certain
antivenoms (EchiTab ICP-Plus) raised against Nigeriansnakes have been confirmed as extending to other spe-
cies by means of antivenomics [36]. As only about 8.5%
of snakebite victims attend hospitals in Nigeria people
should be educated and enlightened about the benefits
of orthodox medicine so as to reduce the resulting mor-
bidity and mortality [37].
Certain herbs in Nigeria (Aristolochia albida, Guiera
senegalensis, Schumaniophyton magnificum etc.) were
found to act on snake venoms in experimental animals
but studies are ongoing and remain inconclusive [38-40].
Their use as accessory and supplementary agents should
be evaluated further.
Recommendations
Expert advice and encouragement must be offered to
Nigerian health authorities, regulatory agencies, anti-
venom producers and medical personnel to improve
every aspect of snakebite treatment. In particular:
 Antivenom manufacturers must be helped in
practical ways to improve the safety and efficacy
of their products. This requires the design and
implementation of long-term technology
transfer programs involving both North–south
(i.e., collaborations between institutions in developed
and developing countries such as between the
United Kingdom and Nigeria) and South-South
partnerships (i.e., collaborations between two
institutions in the developing world such as between
institutions in Nigeria and Brazil or Costa Rica).
 National health authorities must be helped to select
and purchase antivenoms appropriate to their
national needs.
 Adequate policies for antivenom distribution must
be developed in the country and in each health zone
(or state) in order to provide antivenoms where they
are most needed. There should be sufficient political
will to prevent any exhaustion of antivenom stock,
even a temporary one.
 Medical personnel must be trained in the modern
management of snakebites and, most crucially, in
the selective use of antivenoms through the use of
educational pamphlets, as well as lectures and
practical demonstrations.
 Undergraduate and post-graduate training of
medical students, nurses and community health care
workers should incorporate ophidian, scorpion and
spider envenoming in their curriculum.
 Communities must be informed and educated about
snakebite risks through the use of posters and
leaflets. They should be offered realistic solutions
that mitigate the hazards and empower the people
themselves to help manage the problem in practical
and sustainable ways.
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methods of first aid, primary clinical care and
patient rehabilitation must be accorded priority and
funded at national and state levels.
 Surveillance and reporting systems that enable
collation of reliable epidemiological and clinical data
need to be developed, tested and implemented; and
the data used to support rational resource allocation
and distribution, and appropriate prioritization of
snakebite envenoming as a neglected tropical disease
at all levels.
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